Ran-Hui Cha

Ran-Hui Cha

Auto-generated profile, based on publicly available information

Ran-Hui Cha

Department of Internal Medicine, National Medical Center, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
RCRan-Hui Cha
Ran-Hui Cha
JJJoon-Sung Joh
Joon-Sung Joh
IJIna Jeong
Ina Jeong
JLJi Yeon Lee
Ji Yeon Lee
HSHyoung-shik Shin
Hyoung-shik Shin
CCCritical Care Team of National Medical Center
Critical Care Team of National Medical Center
Cha RH, et al. J Korean Med Sci. 2015 Dec;30(12):1807-1814. http://dx.doi.org/10.3346/jkms.2015.30.12.1807

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
RCRan-Hui Cha
Ran-Hui Cha
SYSeung Hee Yang
Seung Hee Yang
KMKyung Chul Moon
Kyung Chul Moon
JJJoon-Sung Joh
Joon-Sung Joh
JLJi Yeon Lee
Ji Yeon Lee
YKYon Su Kim
Yon Su Kim
Cha RH, et al. J Korean Med Sci. 2016 Apr;31(4):635-640. http://dx.doi.org/10.3346/jkms.2016.31.4.635

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JRJiwon Ryu
Jiwon Ryu
RCRan-Hui Cha
Ran-Hui Cha
DKDong Ki Kim
Dong Ki Kim
JLJu Hyun Lee
Ju Hyun Lee
SYSun Ae Yoon
Sun Ae Yoon
AIAPrODiTe investigators
APrODiTe investigators
Ryu J, et al. J Korean Med Sci. 2014 Jul;29(7):957-964. https://doi.org/10.3346/jkms.2014.29.7.957

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
RCRan-Hui Cha
Ran-Hui Cha
GLGeum Sil Lee
Geum Sil Lee
JYJu Yeon Yoo
Ju Yeon Yoo
OROe Bog Rhee
Oe Bog Rhee
YJYong Duk Jeon
Yong Duk Jeon
Cha RH, et al. J Korean Med Sci. 2021 Mar;36(11):e76. https://doi.org/10.3346/jkms.2021.36.e76

31 March 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
RCRan-Hui Cha
Ran-Hui Cha
Inflammation, metabolic acidosis, renin-angiotensin system activation, insulin resistance, and impaired perfusion to skeletal muscles, among others, are possible causes of uremic sarcopenia. These conditions induce the activation of the nuclear factor-kappa B and mitogen-activated protein kinase pathways, adenosine triphosphate ubiquitin-proteasome system, and reactive oxygen species system, resulting in protein catabolism. Strategies for the prevention and treatment of sarcopenia in chronic kidney disease (CKD) are aerobic and resistance exercises along with nutritional interventions. Anabolic hormones have shown beneficial effects. Megestrol acetate increased weight, protein catabolic rate, and albumin concentration, and it increased intracellular water component and muscle mass. Vitamin D supplementation showed improvement in physical function, muscle strength, and muscle mass. Correction of metabolic acidosis showed an increase in protein intake, serum albumin levels, body weight, and mid-arm circumference. The kidney- gut-muscle axis indicates that dysbiosis and changes in gut-derived uremic toxins and short-chain fatty acids affect muscle mass, composition, strength, and functional capacity. Biotic supplements, AST-120 administration, hemodiafiltration, and preservation of residual renal function are alleged to reduce uremic toxins, including indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Synbiotics reversed the microbiota change in CKD patients and decreased uremic toxins. AST-120 administration changed the overall gut microbiota composition in CKD. AST-120 prevented IS and PCS tissue accumulation, ameliorated muscle atrophy, improved exercise capacity and mitochondrial biogenesis, restored epithelial tight junction proteins, and reduced plasma endotoxin levels and markers of oxidative stress and inflammation. In a human study, the addition of AST-120 to standard treatment had modest beneficial effects on gait speed change and quality of life.

9 August 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YKYong Chul Kim
Yong Chul Kim
KKKyu Hong Kim
Kyu Hong Kim
SLSunhwa Lee
Sunhwa Lee
JJJi‐Won Jo
Ji‐Won Jo
JPJae Yoon Park
Jae Yoon Park
SYSeung Hee Yang
Seung Hee Yang
Peritoneal fibrosis (PF) is an intractable complication of peritoneal dialysis (PD) that leads to peritoneal membrane failure. This study investigated the role of suppression of tumorigenicity (ST)2 in PF using patient samples along with mouse and cell‐based models. Baseline dialysate soluble (s)ST2 level in patients measured 1 month after PD initiation was 2063.4 ± 2457.8 pg/mL; patients who switched to haemodialysis had elevated sST2 levels in peritoneal effluent (1576.2 ± 199.9 pg/mL, P = .03), which was associated with PD failure ( P = .04). Baseline sST2 showed good performance in predicting PD failure (area under the receiver operating characteristic curve = 0.780, P = .001). In mice with chlorhexidine gluconate‐induced PF, ST2 was expressed in fibroblasts and mesothelial cells within submesothelial zones. In primary cultured human peritoneal mesothelial cells (HPMCs), transforming growth factor‐β treatment increased ST2, fibronectin, β‐galactosidase and Snail protein levels and decreased E‐cadherin level. Anti‐ST2 antibody administration reversed the up‐regulation of ST2 and fibronectin expression; it also reduced fibrosis induced by high glucose (100 mmol/L) in HPMCs. Thus, high ST2 level in dialysate is a marker for fibrosis and inflammation during peritoneal injury, and blocking ST2 may be an effective therapeutic strategy for renal preservation.